Anthropic’s Claude Opus 5.5 may have passed a Turing‑style test, sparking debate about true AGI while OpenAI gears up with GPT‑7‑8 and a $500‑a‑month Pro Max plan.
Japan’s breakthrough tooth‑regrowth drug blocks USAG‑1, showing promise in Phase I and targeting children with congenital tooth loss—could it replace implants?
Autonomous labs run by GPT‑6 Astra could speed breakthroughs in biology, chemistry and materials science—yet raise safety, cost and alignment concerns.
AI rapidly reshapes medicine—clinically tested AI now outperforms doctors in ERs, discovers new drugs, and sparks a debate on cost, workforce, and ethics.
Google’s upcoming SpaceX launch aims to test orbital AI data centers, exploring cost, cooling challenges and geopolitical risks for future space‑based computing.
Intelligence costs are plummeting—dropping ~50% quarterly, faster than DNA, compute, or batteries—while AI models launch faster, sparking debate on local AI in everyday devices.
Anthropic’s Claude AI uncovers a novel enzyme system in phage DNA, mirroring CRISPR‑like repeats, showing how AI‑driven research can accelerate biotech discoveries.